– establishing U.S. manufacturing footprint – BASEL, Switzerland, Sept. 2, 2025 -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients from natural sources, announced today the signing of a binding and definitive agreement to acquire the multipurpose production site in Thomson, IL from International Flavors & Fragrances, Inc. (IFF). "This acquisition is an important step in delivering on our strategic capacity expansion in North America," said Bruno Tremblay, Chief Executive Officer of Jungbunzlauer. "Establishing a U.S. manufactu
SYDNEY, Sept. 2, 2025 -- A humble lunch video from world-renowned cardiologist Dr. Hosen Kiat has captured more than 230,000 views on Chinese social media Little Red Book. Shared as part of his new digital wellness initiative with Heartbeats, the "real-style" post featured nothing more than a cup of black coffee, a vegetarian sandwich, steamed vegetables, and mushrooms - yet it sparked a wave of engagement across cultures. Watch the original post here. Despite being filmed in English, the clip resonated deeply with Chinese audiences, proving that authentic science-based healt
BANGKOK, Sept. 2, 2025 -- SteriLance Medical announced that its safety lancet portfolio — PRESS PLUS, IMPRESS and LITE3 — has been adopted within Thailand's public-hospital channels following a tender awarded by a nationally recognized humanitarian organization. Supply and post-market support are being delivered through an authorized local distributor holding Thai FDA registrations. Engineered to reduce accidental needle exposure and improve user comfort in high-throughput settings, SteriLance safety lancets feature single-use auto-retraction and low-pain skin entry, supporting
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 -- LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals. By aligning with its partner's meaningful
[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 9월 1일 -- 제92회 중국국제의료기기박람회(China International Medical Equipment Fair, CMEF 2025) 하반기(가을) 행사가 9월 26일부터 29일까지 광저우 중국수출입상품교역전시관(China Import and Export Fair Complex, 캔톤 페어 전시장)에서 열릴 예정이다. '건강, 혁신, 협업(Health, Innovation, Collaboration)'을 주제로 한 이번 박람회는 글로벌 헬스케어 업계를 한자리에 모아 고품질 개발을 위한 새로운 기회를 모색한다. CMEF는 국제 최고 수준의 전시회로서 업계 전반의 전 세계 이해관계자를 결집시키며 혁신 기술 전시, 파트너십 및 브랜드 협력, 학술 교류, 트렌드 인사이트, 교육을 통해 글로벌 헬스케어의 고품질 성장을 견인한다. CMEF 2025는 약 20만㎡ 규모로 열리며 약 4000개 기업과 12만 명의 전문가가 참가할 예정이다. 이번 박람회는 의료 영상, 체외 진단, 수술 로봇, 스마트 헬스케어 등 28개 테마 존을 구성해, 연구개발부터 최종 사용자 응용
[ 메디채널 김갑성 기자 ] "Quantum AI up to 73x Faster on NVIDIA CUDA-Q" Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. The company has secured use cases for quantum AI in drug development and plans to expand validation efforts into various fields. SEOUL, South Korea, Sept. 1, 2025 -- Quantum computing company Norma (CEO Hyunchul Jung, www.norma.co.kr) has achieved over 73× faster
AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction SEOUL, South Korea, Sept. 1, 2025 -- AMI Pharm's novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin. The clinical data from the trial was recen
[ 메디채널 김갑성 기자 ] 서울 대한민국 2025년 9월 1일 -- 글로벌 바이오텍 기업 아크로바이오시스템즈(ACROBiosystems)와 임상 단계 바이오기업 다안바이오테라퓨틱스(Daan Biotherapeutics)가 정밀 면역항암제 개발을 위한 전략적 양해각서(MOU)를 체결했다고 밝혔다. 이번 협약을 통해 양사는 고기능성 바이오시약의 안정적 공급, 면역항암제 개발을 위한 기술 협력, 공동 연구 및 데이터 공유 등 다각적 협력 체계를 구축하고, 정밀 면역치료제의 연구개발 및 상용화를 가속화할 계획이다. 아크로바이오시스템즈는 재조합 단백질, 키트, 항체, 과학 서비스 등을 제공하는 바이오텍 기업으로, 신약 개발에 혁신적인 솔루션을 제공하고 있다. 특히 세포유전자 치료제의 CMC 단계를 위해, 고품질의 GMP 등급 원료 및 품질관리(QC) 솔루션을 포함하는 Resilient Supply™ 라는 자체 브랜드를 론칭하여 생산 유연성과 규제 준수 측면에서 고객사의 니즈를 충족시키고 있다. 또한, 스마트 모듈형 설계와 ISO 9001/GMP 인증을 갖춘 GMP 생산 기지를 보유하여, 사이토카인, 세포치료제 활성화용 항
POTSDAM, Germany, Sept. 1, 2025 -- Data4Life announces that the Hasso Plattner Foundation, as the supporting foundation of the organization, has appointed Dr. Ben Illigens as its new Chief Executive Officer (CEO). He succeeds Christian Weiss, who has shaped the development phase of Data4Life since 2017 and will continue to advise the organization in a consulting role. With more than 15 years of experience at the intersection of clinical research, digital transformation, and global health initiatives, Dr. Illigens brings extensive expertise in neurology, oncology, digital health strateg
PHOENIX, Sept. 1, 2025 -- Today marks the official launch of FitTransformer, a revolutionary fitness brand redefining how people train at home. Combining cutting-edge engineering, space-saving design, and intelligent performance tracking, FitTransformer introduces the first modular system that transforms seamlessly between cardio and strength training—without taking up an entire room. "We created FitTransformer to eliminate the complexity, clutter, and cost of traditional gym equipment," says Sam, Founder and CEO of FitTransformer. "Whether you live in a studio o